Safety and immunologic correlates of Melanoma GVAX a GM-CSF secreting allogeneic melanoma cell vaccine administered in the adjuvant setting

摘要

BackgroundLimited adjuvant treatment options exist for patients with high-risk surgically resected melanoma. This first-in-human study investigated the safety, tolerability and immunologic correlates of Melanoma GVAX, a lethally irradiated granulocyte–macrophage colony stimulating factor (GM-CSF)-secreting allogeneic whole-cell melanoma vaccine, administered in the adjuvant setting.